Extending aromatase inhibitor sensitivity in hormone resistant breast cancer

Hormone Molecular Biology and Clinical Investigation

Volumn 5, Issue 2, 2011, Pages 97-103

  Brodie, Angela M H ^a,b   Sabnis, Gauri J ^a   Chumsri, Saranya ^a,b   Sukumar, Sara ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aromatase inhibitors; breast cancer; letrozole; trastuzumab

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AROMATASE; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN ELK; S6 KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 85021016027     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2011.010     Document Type: Article

References (30)

1. Burstein HJ., Prestrud AA., Seidenfeld J., Anderson H., Buchholz TA., Davidson NE., Gelmon KE., Giordano SH., Hudis CA., Malin J., Mamounas EP., Rowden D., Solky AJ., Sowers MR., Stearns V., Winer EP., Somerfield MR., Griggs JJ. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-96.
2. The American Cancer Society A., Georgia. Breast cancer facts & figures 2009-2010.
3. Jelovac D., Sabnis G., Long BJ., Macedo L., Goloubeva OG., Brodie AM. Activation of mitogen-activated protein kinase in xeno-grafts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 2005;65:5380-9.
4. Sabnis G., Goloubeva O., Jelovac D., Schayowitz A., Brodie A. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 2007;13:2751-7.
5. Sabnis G., Schayowitz A., Goloubeva O., Macedo L., Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009; 69:1416-28.
6. Sabnis GJ., Macedo LF., Goloubeva O., Schayowitz A., Brodie AM. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 2008;68:4518-24.
7. Sabnis G., Goloubeva O., Gilani R., Macedo L., Brodie A. Sensitivity to the aromatase inhibitor letrozole is prolonged after a ''break'' in treatment. Mol Cancer Therap 2010;9:46-56.
8. Sabnis GJ., Macedo L., Goloubeva O., Schayowitz A., Zhu Y., Bro-die A. Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol 2008;108:1-7.
9. Sabnis GJ., Jelovac D., Long B., Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65:3903-10.
10. Long BJ., Jelovac D., Handratta V., Thiantanawat A., MacPherson N., Ragaz J., Goloubeva O., Brodie AM. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004;96:456-65.
11. Kazi AA., Jones JM., Koos RD. Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypox-ia-inducible factor 1 to the vascular endothelial growth factor promoter. Mol Endocrinol 2005;19:2006-19.
12. Jelovac D., Macedo L., Goloubeva OG., Handratta V., Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65:5439-44.
13. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., Metzger D., Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
14. Joel PB., Traish AM., Lannigan DA. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 1998;273:13317-23.
15. Chen D., Washbrook E., Sarwar N., Bates GJ., Pace PE., Thiru-nuvakkarasu V., Taylor J., Epstein RJ., Fuller-Pace FV., Egly JM., Coombes RC., Ali S. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002;21:4921-31.
16. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
17. Lipton A., Leitzel K., Ali SM., Demers L., Harvey HA., Chaudri-Ross HA., Evans D., Lang R., Hackl W., Hamer P., Carney W. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005;104:257-63.
18. Lipton A., Ali S., Leitzel K. HER-2 protein expression predicts response to trastuzumab in FISH-positive patients with meta-static breast cancer. In: 31st AACR-CTRC San Antonio Breast Cancer Symposium 2008, San Antonio., TX, USA., 2008.
19. Flageng MH., Moi LL., Dixon JM., Geisler J., Lien EA., Miller WR., Lonning PE., Mellgren G. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 2009;10:1253-60.
20. Marcom PK., Isaacs C., Harris L., Wong ZW., Kommarreddy A., Novielli N., Mann G., Tao Y., Ellis MJ. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-9.
21. Mackey J., Kaufman B., Clemens M. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-posi-tive metastatic breast cancer. Breast Cancer Res Treat 2006; 100(Suppl 1):abstract 3.
22. Johnston S., Pippen J Jr., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez HL., Romieu G., Manikhas A., Kennedy MJ., Press MF., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
23. Hammond ME., Hayes DF., Dowsett M., Allred DC., Hagerty KL., Badve S., Fitzgibbons PL., Francis G., Goldstein NS., Hayes M., Hicks DG., Lester S., Love R., Mangu PB., McShane L., Miller K., Osborne CK., Paik S., Perlmutter J., Rhodes A., Sasano H., Schwartz JN., Sweep FC., Taube S., Torlakovic EE., Valenstein P., Viale G., Visscher D., Wheeler T., Williams RB., Wittliff JL., Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immu-nohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
24. Ottaviano YL., Issa JP., Parl FF., Smith HS., Baylin SB., Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994;54:2552-5.
25. Lapidus RG., Nass SJ., Butash KA., Parl FF., Weitzman SA., Graff JG., Herman JG., Davidson NE. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 1998;58:2515-9.
26. Ferguson AT., Lapidus RG., Baylin SB., Davidson NE. Deme- thylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995;55:2279-83.
27. Yang X., Phillips DL., Ferguson AT., Nelson WG., Herman JG., Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001;61:7025-9.
28. Sabnis G., Goloubeva O., Chumsri S., Nguyen N., Sukumar S., Brodie A. Functional activation of the estrogen receptor-a and aromatase by the HDAC inhibitor., entinostat, sensitizes of ER-negative tumors to letrozole. Cancer Res 2011;71:1893-903.
29. Azuma K., Urano T., Horie-Inoue K., Hayashi S., Sakai R., Ouchi Y., Inoue S. Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 2009;69:2935-40.
30. Munzone E., Curigliano G., Rocca A., Bonizzi G., Renne G., Goldhirsch A., Nole F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 2006;8:R4.